Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease

Journal of Psychiatric Research

Volumn 43, Issue 8, 2009, Pages 749-753

  Popp, Julius ^a   Bacher, Michael ^b   Kölsch, Heike ^a   Noelker, Carmen ^b   Deuster, Oliver ^b   Dodel, Richard ^b   Jessen, Frank ^a  

^a UNIVERSITY OF BONN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Alzheimer's disease; Amnestic mild cognitive impairment; Cerebrospinal fluid; Macrophage migration inhibitory factor; Neuroinflammation

Indexed keywords

APOLIPOPROTEIN E4; GAMMA INTERFERON; INTERLEUKIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; FEMALE; HUMAN; INFLAMMATION; MACROPHAGE MIGRATION INHIBITION; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION DISORDERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-6; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 64249099065     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2008.10.006     Document Type: Article

References (38)

1. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., et al. Inflammation and Alzheimer's disease. Neurobiology of Aging 21 3 (2000) 383-421
2. Bacher M., Meinhardt A., Lan H.Y., Dhabhar F.S., Mu W., Metz C.N., et al. MIF expression in the rat brain: implications for neuronal function. Molecular Medicine 4 4 (1998) 217-230
3. Bellinger F.P., Madamba S.G., Campbell I.L., and Siggins G.R. Reduced long-term potentiation in the dentate gyrus of transgenic mice with cerebral overexpression of interleukin-6. Neuroscience Letter 198 2 (1995) 95-98
4. Blum-Degen D., Muller T., Kuhn W., Gerlach M., Przuntek H., and Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neuroscience Letter 202 1-2 (1995) 17-20
5. Cagnin A., Brooks D.J., Kennedy A.M., Gunn R.N., Myers R., Turkheimer F.E., et al. In vivo measurement of activated microglia in dementia. Lancet 358 9280 (2001) 461-467
6. Calandra T., and Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Natural Reviews Immunology 3 10 (2003) 791-800
7. Chao C.C., Hu S., Ehrlich L., and Peterson P.K. Interleukin-1 and tumor necrosis factor-alpha synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-D-aspartate receptors. Brain Behavior and Immunity 9 4 (1995) 355-365
8. Combs C.K., Karlo J.C., Kao S.C., and Landreth G.E. Beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. Journal of Neuroscience 21 4 (2001) 1179-1188
9. Cvetkovic I., Al-Abed Y., Miljkovic D., Maksimovic-Ivanic D., Roth J., Bacher M., et al. Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology 146 7 (2005) 2942-2951
10. de Leon M.J., DeSanti S., Zinkowski R., Mehta P.D., Pratico D., Segal S., et al. MRI and CSF studies in the early diagnosis of Alzheimer's disease. Journal Internal Medicine 256 3 (2004) 205-223
11. Donn R.P., and Ray D.W. Macrophage migration inhibitory factor: molecular, cellular and genetic aspects of a key neuroendocrine molecule. Journal of Endocrinology 182 1 (2004) 1-9
12. Engelborghs S., De Brabander M., De Crée J., D'Hooge R., Geerts H., Verhaegen H., et al. Unchanged levels of interleukins, neopterin, interferon-gamma and tumor necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type. Neurochemistry International 34 6 (1999) 523-530
13. Galimberti D., Schoonenboom N., Scheltens P., Fenoglio C., Bouwman F., Venturelli E., et al. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Archives of Neurology 63 4 (2006) 538-543
14. Griffin W.S., Sheng J.G., Roberts G.W., and Mrak R.E. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. Journal of Neuropathology and Experimental Neurology 54 2 (1995) 276-281
15. Hampel H., Schoen D., Schwarz M.J., Kotter H.U., Schneider C., Sunderland T., et al. Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease. Neuroscience Letter 228 3 (1997) 143-146
16. Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Dewachter I., Walter J., Klockgether T., et al. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. Journal of Neuroinflammation 2 (2005) 22
17. Hixson J.E., Vernier D.T., and Powers P.K. Detection of SstI restriction site polymorphism in human APOC3 by the polymerase chain reaction. Nucleic Acids Research 19 (1991) 196
18. Hong H.S., Hwang E.M., Sim H.J., Cho H.J., Boo J.H., Oh S.S., et al. Interferon-gamma stimulates beta-secretase expression and sAPPbeta production in astrocytes. Biochemical and Biophysical Research Communications 307 4 (2003) 922-927
19. Hull M., Berger M., Volk B., and Bauer J. Occurrence of interleukin-6 in cortical plaques of Alzheimer's disease patients may precede transformation of diffuse into neuritic plaques. Annals of the New York Academy of Sciences 777 (1996) 205-212
20. Kofoed K., Schneider U.V., Scheel T., Andersen O., and Eugen-Olsen J. Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology. Clinical Chemistry 52 7 (2006) 1284-1293
21. Kropholler M.A., Boellaard R., van Berckel B.N., Schuitemaker A., Kloet R.W., Lubberink M.J., et al. Evaluation of reference regions for (R)-[(11)C]PK11195 studies in Alzheimer's disease and Mild Cognitive Impairment. Journal of Cerebral Blood Flow and Metabolism 27 12 (2007) 1965-1974
22. Lanzrein A.S., Johnston C.M., Perry V.H., Jobst K.A., King E.M., and Smith A.D. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Disease and Associated Disorders 12 3 (1998) 215-227
23. Magaki S., Mueller C., Dickson C., and Kirsch W. Increased production of inflammatory cytokines in mild cognitive impairment. Experimental Gerontology 42 3 (2007) 233-240
24. McCusker S.M., Curran M.D., Dynan K.B., McCullagh C.D., Urquhart D.D., Middleton D., et al. Association between polymorphism in regulatory region of gene encoding tumor necrosis factor-alpha and risk of Alzheimer's disease and vascular dementia: a case-control study. Lancet 357 9254 (2001) 436-439
25. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 7 (1984) 939-944
26. Meyer-Siegler K. Increased stability of macrophage migration inhibitory factor (MIF) in DU-145 prostate cancer cells. Journal of Interferon and Cytokine Research 20 9 (2000) 769-778
27. Morris J.C., Heyman A., Mohs R.C., Hughes J.P., van Belle G., Fillenbaum G., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39 9 (1989) 1159-1165 September
28. Oyama R., Yamamoto H., and Titani K. Glutamine synthetase, hemoglobin alpha-chain, and macrophage migration inhibitory factor binding to amyloid- beta-protein: their identification in rat brain by a novel affinity chromatography and in Alzheimer's disease brain by immunoprecipitation. biochimica et Biophysica Acta 1479 1-2 (2000) 91-102
29. Papassotiropoulos A., Bagli M., Jessen F., Bayer T.A., Maier W., Rao M.L., et al. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. Annals of Neurology 45 5 (1999) 666-668
30. Ramos E.M., Lin M.T., Larson E.B., Maezawa I., Tseng L.H., Edwards K.L., et al. Tumor necrosis factor-alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease. Archives of Neurology 63 8 (2006) 1165-1169
31. Rota E., Bellone G., Rocca P., Bergamasco B., Emanuelli G., and Ferrero P. Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. Neurology Science 27 1 (2006) 33-39
32. Tarkowski E., Blennow K., Wallin A., and Tarkowski A. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. Journal of Clinical Immunology 19 4 (1999) 223-230
33. Tarkowski E., Andreasen N., Tarkowski A., and Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. Journal of Neurology Neurosurgery and Psychiatry 74 9 (2003) 1200-1205
34. Wada-Isoe K., Wakutani Y., Urakami K., and Nakashima K. Elevated interleukin-6 levels in cerebrospinal fluid of vascular dementia patients. Acta Psychiatrica Scandinavica 110 2 (2004) 124-127
35. Winblad B., Palmer K., Kivipelto M., Jelic V., Fratiglioni L., Wahlund L.O., et al. Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine 256 3 (2004) 240-246
36. Yamada K., Kono K., Umegaki H., Yamada K., Iguchi A., Fukatsu T., et al. Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia. Neuroscience Letter 186 2-3 (1995) 219-221
37. Yamamoto M., Kiyota T., Horiba M., Buescher J.L., Walsh S.M., Gendelman H.E., et al. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. American Journal of Pathology 170 2 (2007) 680-692
38. Zhong Z., Ewers M., Teipel S., Burger K., Wallin A., Blennow K., et al. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Archives of General Psychiatry 64 6 (2007) 718-726